Fort Wayne Oncology & Hematology, Inc.

Fort Wayne, Indiana 46845

0 studies enrolling now · 27 studies all time

What they study most

Bladder Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, Lung Cancer, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Malignant Neoplasm of Breast, Metastatic Breast Cancer, Non-Small Cell Lung Cancer

Studies at this site

• PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations — Completed
• Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer — Completed
• Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC — Completed
• BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma — Completed
• Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer — Completed
• A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer — Stopped early
• Sutent + Taxol for Advanced Esophageal Cancer — Completed
• Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma — Stopped early
• Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer — Completed
• A Biological Sample Collection Protocol of Women With and Without Breast Cancer — Completed
• Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer — Completed
• Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer — Stopped early
• Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer — Stopped early
• Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer — Stopped early
• Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer — Completed
• Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer — Completed
• Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer — Stopped early
• Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer — Completed
• Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas — Stopped early
• Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer — Completed
• PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer — Stopped early
• A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer — Stopped early
• Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Stopped early
• Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck — Stopped early
• Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer — Stopped early
• Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer — Stopped early
• A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer — Completed